Moderna's stock plunged on Thursday, startling investors. But the company remains one of this year’s hottest biotech ...

Moderna gave investors a scare as its stock plunged on Thursday. But it's still one of the hottest biotechs this year. And it's hardly alone – the sector is on a roll and looks poised for more gains.

A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma avoid cancer recurrence. The combination trains the patient's immune system ...

When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

Moderna and Merck are preparing to seek regulatory approval after their experimental melanoma vaccine delivered promising ...

“This is the first step,” said Dr. Robert Vonderheide, president-elect of the American Association for Cancer Research and ...

A new personalized mRNA vaccine for melanoma is being hailed by some oncologists as a major breakthrough after it reduced the risk of cancer recurrence and death by 42% compared with standard ...

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial in melanoma, oncologists and the public alike were ...

Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...

Moderna launched its coronavirus vaccine in early pandemic days and saw revenue and stock performance skyrocket. As demand ...

Tempus AI delivers robust 22% YoY revenue growth, forecasting $1.6bn in 2026 and demonstrating strong commercial traction.